Graham Capital Management L.P. Purchases 16,128 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Graham Capital Management L.P. increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 37.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,129 shares of the biopharmaceutical company's stock after purchasing an additional 16,128 shares during the quarter. Graham Capital Management L.P. owned 0.06% of Ultragenyx Pharmaceutical worth $2,488,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of RARE. Smartleaf Asset Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 493 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $35,000. Human Investing LLC purchased a new stake in Ultragenyx Pharmaceutical during the fourth quarter worth approximately $42,000. Van ECK Associates Corp increased its stake in Ultragenyx Pharmaceutical by 18.4% during the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 273 shares during the period. Finally, Quarry LP bought a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $84,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE traded up $0.61 on Friday, hitting $35.45. 204,169 shares of the company were exchanged, compared to its average volume of 825,993. The firm has a market capitalization of $3.35 billion, a P/E ratio of -5.59 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.59 and a twelve month high of $60.37. The company's 50 day moving average price is $36.45 and its 200-day moving average price is $41.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The business had revenue of $139.29 million for the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. Ultragenyx Pharmaceutical's revenue for the quarter was up 28.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($2.03) EPS. As a group, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. HC Wainwright reaffirmed a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. JPMorgan Chase & Co. boosted their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Piper Sandler cut their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. Finally, Canaccord Genuity Group raised their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $90.93.

Insiders Place Their Bets

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the transaction, the executive vice president now directly owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. This trade represents a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Theodore Alan Huizenga sold 967 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the transaction, the chief accounting officer now owns 50,265 shares in the company, valued at approximately $2,116,156.50. This trade represents a 1.89% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 125,405 shares of company stock valued at $5,285,169 in the last 90 days. 5.50% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.